|
Alkermes: Targeting addiction treatment |
|
| Dec 03, 2009 09:00 PM UTC |
|
Tracked Blogger
|
Via BloggingStocks:
Filed under: Stocks to Buy "Alkemes (NASDAQ: ALKS) recentlyy announced positive Phase 3 results testing naltrexone for extended-release injectable suspension for the treatment of opioid dependence," says biotech specialist John McCamant. In The Medical technology Stock Letter, he explains, "In addition to the use of heroin, opioid abuse and addiction includes prescription pain relievers, and represents a growing public health problem in the U.S. and a significant opportunity for the company." Continue reading Alkermes: Targeting addiction treatment Alkermes: Targeting addiction treatment originally appeared on BloggingStocks on Thu, 03 Dec 2009 16:00:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments
Read the rest of original post »
|
Comments (3)
Add Comment
Your Comment
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |
